S.Biomedics Co., Ltd. (KOSDAQ:304360)

South Korea flag South Korea · Delayed Price · Currency is KRW
21,700
+700 (3.33%)
At close: Apr 24, 2025, 3:30 PM KST
-50.85%
Market Cap 254.88B
Revenue (ttm) 13.73B
Net Income (ttm) -6.69B
Shares Out 11.75M
EPS (ttm) -581.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 179,653
Average Volume 169,530
Open 21,000
Previous Close 21,000
Day's Range 20,750 - 22,600
52-Week Range 16,130 - 51,600
Beta n/a
RSI 45.61
Earnings Date May 9, 2025

About S.Biomedics

S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson’s disease; FECS-Ad, which is 1/2a for the treatment of critical limb ischemia; FECS-DF, which is in phase 1/2 clinical development for the treatment of crows feet; TED-R for the treatment of macular degeneration... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2005
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 304360
Full Company Profile

Financial Performance

In 2024, S.Biomedics's revenue was 13.73 billion, an increase of 4.77% compared to the previous year's 13.11 billion. Losses were -6.69 billion, -35.17% less than in 2023.

Financial Statements

News

There is no news available yet.